Comments on ‘Search for tumor-specific frequencies of amplitude modulated 27 MHz electromagnetic fields in mice with hepatocarcinoma xenografted tumors’

"Comments on ‘Search for tumor-specific frequencies of amplitude modulated 27 MHz electromagnetic fields in mice with hepatocarcinoma xenografted tumors’." International Journal of Radiation Biology, 96(7), pp. 845–846

Disclosure statement

Hugo Jimenez has nothing to disclose. Sambad Sharma has nothing to disclose. Kimberly Sheffield has nothing to disclose. Kojo Agyemang has nothing to disclose. Allan Johansen has nothing to disclose. Carl Blackman reports that he has provided a loan to TheraBionic Inc. Kounosuke Watabe has nothing to disclose.

Alexandre Barbault reports other from TheraBionic Inc., other from TheraBionic GmbH, outside the submitted work; In addition, Dr. Barbault has a patent European Patent # 2139557 licensed to TheraBionic Inc., a patent U.S. patent # 8.977.365 B2 licensed to TheraBionic Inc., a patent Australian patent # 2008232041 licensed to TheraBionic Inc., a patent Brazil patent # PI0810084-5 licensed to TheraBionic Inc., a patent Canada patent # 2,682,322 licensed to TheraBionic Inc., a patent China patent # ZL 200880009864.4 licensed to TheraBionic Inc., a patent Macau patent # J/001431 licensed to TheraBionic Inc., a patent Israel patent # 201099 licensed to TheraBionic Inc., a patent Japan patent # 5435240 licensed to TheraBionic Inc., a patent Korea patent # 10-1478582 licensed to TheraBionic Inc., a patent Mexico patent # 318857 licensed to TheraBionic Inc., a patent Russia patent # 2594824 licensed to TheraBionic Inc., a patent Saudi Arabia patent # 3075 licensed to TheraBionic Inc., a patent Singapore patent # 155671 licensed to TheraBionic Inc., a patent South Africa patent # 2009/06700 licensed to TheraBionic Inc., and a patent United Arab Emirates patent # P849/09 licensed to TheraBionic Inc.

Boris Pasche reports other from TheraBionic Inc., other from TheraBionic GmbH, other from Rafael Holdings, Inc., outside the submitted work; In addition, Dr. Pasche has a patent Europe # 2139557 licensed to TheraBionic Inc., a patent U.S. # 8.977.365 B2 licensed to TheraBionic Inc., a patent Australia # 2008232041 licensed to TheraBionic Inc., a patent Brazil # PI0810084-5 licensed to TheraBionic Inc., a patent Canada # 2,682,322 licensed to TheraBionic Inc., a patent China # ZL 200880009864.4 licensed to TheraBionic Inc., a patent Macau # J/001431 licensed to TheraBionic Inc., a patent Israel # 201099 licensed to TheraBionic Inc., a patent Japan # 5435240 licensed to TheraBionic Inc., a patent Korea # 10-1478582 licensed to TheraBionic Inc., a patent Mexico # 318857 licensed to TheraBionic Inc., a patent Russia # 2594824 licensed to TheraBionic Inc., a patent Saudi Arabia # 3075 licensed to TheraBionic Inc., a patent Singapore # 155671 licensed to TheraBionic Inc., a patent South Africa # 2009/06700 licensed to TheraBionic Inc., and a patent United Arab Emirates # P849/09 licensed to TheraBionic Inc.

Additional information

Funding

Boris Pasche reports grants from NCI P30CA0121978, grants from Charles L. Spurr Professorship Funds, during the conduct of the study.

Notes on contributors

Hugo Jimenez

Hugo Jimenez PhD, is a Post-Doctoral Research Fellow in the Department of Cancer Biology, Wake Forest Baptist Medical Center, North Carolina, USA

Sambad Sharma

Sambad Sharma PhD, is a Post-Doctoral Research Fellow in the Department of Cancer Biology, Wake Forest Baptist Medical Center, North Carolina, USA

Kimberly Sheffield

Kimberly Sheffield MS, is a Research Assistant in the Department of Cancer Biology, Wake Forest Baptist Medical Center, North Carolina, USA

Kojo Agyemang

Kojo Agyemang MS, is a doctoral graduate student in the Department of Cancer Biology, Wake Forest Baptist Medical Center, North Carolina, USA

Allan Johansen

Allan Johansen Msc, is a doctoral graduate student in the Department of Cancer Biology, Wake Forest Baptist Medical Center, North Carolina, USA

Carl Blackman

Carl Blackman PhD, is an Adjunct Professor in the Department of Cancer Biology, Wake Forest Baptist Medical Center, North Carolina, USA

Kounosuke Watabe

Kounosuke Watabe PhD, is a Professor in the Department of Cancer Biology, Wake Forest Baptist Medical Center, North Carolina, USA

Alexandre Barbault

Alexandre Barbault is CEO, TheraBionic Gmbh, Ettlingen, Germany

Boris Pasche

Boris Pasche MD PhD, is the Chairman of the Department of Cancer Biology and Director of the Comprehensive Cancer Center at Wake Forest Baptist Medical Center, North Carolina, USA; CEO of TheraBionic Inc. and co-CEO of TheraBionic GmbH